[go: up one dir, main page]

MD20130005A2 - Compoziţie farmaceutică cu eliberare prelungită a trimetazidinei - Google Patents

Compoziţie farmaceutică cu eliberare prelungită a trimetazidinei Download PDF

Info

Publication number
MD20130005A2
MD20130005A2 MDA20130005A MD20130005A MD20130005A2 MD 20130005 A2 MD20130005 A2 MD 20130005A2 MD A20130005 A MDA20130005 A MD A20130005A MD 20130005 A MD20130005 A MD 20130005A MD 20130005 A2 MD20130005 A2 MD 20130005A2
Authority
MD
Moldova
Prior art keywords
trimetazidine
prolonged release
pharmaceutical composition
plasma concentration
release
Prior art date
Application number
MDA20130005A
Other languages
English (en)
Russian (ru)
Other versions
MD4622C1 (ro
MD4622B1 (ro
Inventor
Патрик ЖАНТИ
Кристоф ХЕРМЕЛИН
Жан-Мануэль ПЕАН
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47504206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20130005(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of MD20130005A2 publication Critical patent/MD20130005A2/ro
Publication of MD4622B1 publication Critical patent/MD4622B1/ro
Publication of MD4622C1 publication Critical patent/MD4622C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Invenţia se referă la o compoziţie farmaceutică cu eliberare prelungită a trimetazidinei, în care faza internă cuprinde trimetazidină şi stratul extern cuprinde un agent de întârziere şi un antiaglomerant.Formele cu eliberare prelungită, conform prezentei invenţii, asigură o eliberare treptată şi susţinută pe parcursul a 24 de ore a trimetazidinei la o concentraţie plasmatică eficientă terapeutic şi o disponibilitate a trimetazidinei la o concentraţie plasmatică eficientă terapeutic la scurt timp după administrare.Este descris un procedeu de fabricare a compoziţiei şi utilizarea acesteia în tratamentul profilactic al anginei pectorale, al tulburărilor corioretiniene, precum şi în tratamentul ameţelilor de origine vasculară.
MD20130005A 2012-02-03 2013-02-03 Minigranule cu eliberare prelungită a trimetazidinei MD4622C1 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200322A FR2986431B1 (fr) 2012-02-03 2012-02-03 Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques

Publications (3)

Publication Number Publication Date
MD20130005A2 true MD20130005A2 (ro) 2013-07-31
MD4622B1 MD4622B1 (ro) 2019-03-31
MD4622C1 MD4622C1 (ro) 2019-10-31

Family

ID=47504206

Family Applications (1)

Application Number Title Priority Date Filing Date
MD20130005A MD4622C1 (ro) 2012-02-03 2013-02-03 Minigranule cu eliberare prelungită a trimetazidinei

Country Status (47)

Country Link
US (1) US10117838B2 (ro)
EP (1) EP2623096B1 (ro)
JP (1) JP6338818B2 (ro)
KR (2) KR20130090365A (ro)
CN (2) CN106924221A (ro)
AP (1) AP2013006693A0 (ro)
AR (1) AR089861A1 (ro)
AU (1) AU2013200481B2 (ro)
BR (1) BR102013002524B1 (ro)
CA (1) CA2805471C (ro)
CL (1) CL2013000336A1 (ro)
CO (1) CO6720159A1 (ro)
CR (1) CR20130037A (ro)
CU (1) CU24157B1 (ro)
CY (1) CY1121696T1 (ro)
DK (1) DK2623096T3 (ro)
DO (1) DOP2013000024A (ro)
EA (1) EA030227B1 (ro)
EC (1) ECSP13012415A (ro)
ES (1) ES2735053T3 (ro)
FR (1) FR2986431B1 (ro)
GE (1) GEP20156342B (ro)
GT (1) GT201300032A (ro)
HR (2) HRP20130082A2 (ro)
HU (1) HUE043942T2 (ro)
IL (1) IL224495B (ro)
JO (1) JO3505B1 (ro)
LT (1) LT2623096T (ro)
MD (1) MD4622C1 (ro)
MX (1) MX363302B (ro)
MY (1) MY162599A (ro)
NI (1) NI201300014A (ro)
PE (1) PE20131119A1 (ro)
PH (1) PH12013000031A1 (ro)
PL (1) PL2623096T3 (ro)
PT (1) PT2623096T (ro)
RO (1) RO128004A3 (ro)
RS (2) RS20130034A1 (ro)
RU (1) RU2621128C2 (ro)
SG (1) SG192386A1 (ro)
SI (1) SI2623096T1 (ro)
SV (1) SV2013004396A (ro)
TR (1) TR201906390T4 (ro)
TW (1) TWI508755B (ro)
UA (1) UA118742C2 (ro)
UY (1) UY34595A (ro)
WO (1) WO2013114053A2 (ro)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2675002T3 (es) * 2014-04-08 2018-07-05 Dow Global Technologies Llc Dispersión que comprende un éter de celulosa esterificado
US11123345B2 (en) 2016-11-21 2021-09-21 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법
WO2025068837A2 (en) * 2023-09-26 2025-04-03 Zim Laboratories Limited A novel extended release pharmaceutical composition of trimetazidine or salt thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3080294A (en) * 1960-10-20 1963-03-05 Key Pharma Sustained release type of pharmaceutical vehicles
FR2490963A1 (fr) * 1980-09-30 1982-04-02 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
EP0673649A1 (fr) * 1994-03-24 1995-09-27 Adir Et Compagnie Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale
EP1108424A1 (fr) * 1999-12-17 2001-06-20 Adir Et Compagnie Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale
WO2003043610A2 (en) * 2001-11-21 2003-05-30 Themis Laboratories Private Limited A process for manufacture of a sustained release composition containing microbe
RU2281772C1 (ru) * 2005-02-14 2006-08-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления
CN1994280A (zh) * 2006-12-20 2007-07-11 山东省医药工业研究所 曲美他嗪缓释微丸及其制备方法
RU2362548C1 (ru) * 2007-11-20 2009-07-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
WO2010086868A1 (en) * 2009-01-30 2010-08-05 Lupin Limited Pharmaceutical compositions of trimetazidine
WO2010105673A1 (en) * 2009-03-18 2010-09-23 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60042972D1 (de) * 2000-10-05 2009-10-29 Usv Ltd Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
US20090110728A1 (en) * 2006-05-09 2009-04-30 Suneel Kumar Rastogi Zero-Order Modified Release Solid Dosage Forms
CN101854929A (zh) * 2007-11-09 2010-10-06 田边三菱制药株式会社 新型制剂
WO2010084397A2 (en) * 2009-01-20 2010-07-29 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
EP2394644B1 (en) * 2010-05-04 2014-07-09 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Trimetazidine Formulation With Different Release Profiles

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3080294A (en) * 1960-10-20 1963-03-05 Key Pharma Sustained release type of pharmaceutical vehicles
FR2490963A1 (fr) * 1980-09-30 1982-04-02 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
EP0673649A1 (fr) * 1994-03-24 1995-09-27 Adir Et Compagnie Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale
EP1108424A1 (fr) * 1999-12-17 2001-06-20 Adir Et Compagnie Comprimé matriciel permettant la libération prolongée de trimétazidine après administration par voie orale
WO2003043610A2 (en) * 2001-11-21 2003-05-30 Themis Laboratories Private Limited A process for manufacture of a sustained release composition containing microbe
RU2281772C1 (ru) * 2005-02-14 2006-08-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления
CN1994280A (zh) * 2006-12-20 2007-07-11 山东省医药工业研究所 曲美他嗪缓释微丸及其制备方法
RU2362548C1 (ru) * 2007-11-20 2009-07-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
WO2010086868A1 (en) * 2009-01-30 2010-08-05 Lupin Limited Pharmaceutical compositions of trimetazidine
WO2010105673A1 (en) * 2009-03-18 2010-09-23 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Modified-release dosage (medicine). From Wikipedia, the free encyclopedia. Vizitat ultima dată la 2017.03.24, url: https://en.wikipedia.org/wiki/Modified-release_dosage_(medicine) Chapter Methods, paragraph Micro-encapsulation *

Also Published As

Publication number Publication date
JO3505B1 (ar) 2020-07-05
EP2623096B1 (fr) 2019-04-03
US20130202710A1 (en) 2013-08-08
PE20131119A1 (es) 2013-10-12
CN103239425A (zh) 2013-08-14
CA2805471A1 (fr) 2013-08-03
UY34595A (es) 2013-09-02
HRP20130082A2 (hr) 2013-08-31
BR102013002524A2 (pt) 2014-09-09
MX363302B (es) 2019-03-20
PT2623096T (pt) 2019-05-30
CU24157B1 (es) 2016-03-31
EA030227B1 (ru) 2018-07-31
SI2623096T1 (sl) 2019-06-28
ES2735053T3 (es) 2019-12-13
AU2013200481A1 (en) 2013-08-22
GEP20156342B (en) 2015-08-10
SG192386A1 (en) 2013-08-30
MX2013001118A (es) 2013-08-27
MD4622C1 (ro) 2019-10-31
EP2623096A3 (fr) 2013-10-23
PH12013000031B1 (en) 2014-09-22
CO6720159A1 (es) 2013-07-31
CL2013000336A1 (es) 2014-07-18
EP2623096A2 (fr) 2013-08-07
TW201332591A (zh) 2013-08-16
AR089861A1 (es) 2014-09-24
MD4622B1 (ro) 2019-03-31
KR20150102922A (ko) 2015-09-09
CN106924221A (zh) 2017-07-07
SV2013004396A (es) 2013-06-05
RS20130034A1 (sr) 2013-10-31
RU2013104252A (ru) 2014-08-10
PH12013000031A1 (en) 2014-09-22
CR20130037A (es) 2013-09-18
KR101918211B1 (ko) 2018-11-14
RU2621128C2 (ru) 2017-05-31
DOP2013000024A (es) 2014-07-15
DK2623096T3 (da) 2019-07-15
TR201906390T4 (tr) 2019-05-21
ECSP13012415A (es) 2014-09-30
BR102013002524B1 (pt) 2020-02-04
HUE043942T2 (hu) 2019-09-30
IL224495B (en) 2020-08-31
CY1121696T1 (el) 2020-07-31
GT201300032A (es) 2014-06-09
HRP20191072T1 (hr) 2019-11-01
LT2623096T (lt) 2019-05-10
WO2013114053A3 (fr) 2013-12-19
FR2986431A1 (fr) 2013-08-09
AP2013006693A0 (en) 2013-01-31
NI201300014A (es) 2013-05-13
RO128004A3 (ro) 2013-08-30
EA201300079A2 (ru) 2013-07-30
TWI508755B (zh) 2015-11-21
EA201300079A3 (ru) 2013-11-29
AU2013200481B2 (en) 2015-01-22
RS58752B1 (sr) 2019-06-28
PL2623096T3 (pl) 2019-08-30
NZ606550A (en) 2014-09-26
JP2013159609A (ja) 2013-08-19
UA118742C2 (uk) 2019-03-11
MY162599A (en) 2017-06-30
RO128004A0 (ro) 2012-12-28
US10117838B2 (en) 2018-11-06
KR20130090365A (ko) 2013-08-13
FR2986431B1 (fr) 2017-03-17
WO2013114053A2 (fr) 2013-08-08
JP6338818B2 (ja) 2018-06-06
CA2805471C (fr) 2018-05-01
CU20130016A7 (es) 2014-10-02

Similar Documents

Publication Publication Date Title
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
EP4393487A3 (en) Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
MD20130005A2 (ro) Compoziţie farmaceutică cu eliberare prelungită a trimetazidinei
EA201690962A1 (ru) Составы
NZ702977A (en) 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
WO2012174158A3 (en) Administration of benzodiazepine
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
WO2011086531A3 (en) New anti-malarial agents
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
IN2014MN02236A (ro)
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
HK1216250A1 (zh) 8'-羟基-二氢麦角胺化合物及组合物
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
UA108277C2 (ru) Комплексный препарат, содержащий лерканидипина гидрохлорид и валсартан, и способ его получения
IN2013CH05288A (ro)
WO2013038200A3 (en) Neurodevelopmental disorders
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib
WO2014109725A3 (en) Use of glycyl glutamine against depression
MX2012014498A (es) Composicion farmaceutica de rosuvastatina.

Legal Events

Date Code Title Description
FG4A Patent for invention issued